Development
Precision Bio's PBGENE-HBV demonstrates direct cccDNA elimination in chronic hepatitis B trial
Precision BioSciences (Nasdaq: DTIL) reported the first clinical evidence of direct cccDNA elimination in liver biopsies from patients with chronic...
NEOK Bio doses first patients in Phase I trials of dual bispecific ADCs targeting B7-H3/ROR1 and EGFR/MUC1
NEOK Bio doses first patients in Phase I trials of dual bispecific ADCs targeting B7-H3/ROR1 and EGFR/MUC1
Sobi's olezarsen reduces acute pancreatitis risk by 85% in severe hypertriglyceridemia
Sobi (STO: SOBI) has reported that olezarsen (Tryngolza) reduced the relative risk of acute pancreatitis by 85% and lowered triglycerides by 66% in a pooled...
Jade Bio starts first human study for BAFF-R antibody JADE201 in rheumatoid arthritis
Jade Biosciences (Nasdaq: JBIO), a San Francisco-based clinical-stage biotechnology company, has dosed the first participant in a first-in-human Phase I...
Hansa Biopharma's imlifidase achieves 90% graft survival in kidney transplant desensitization study
Hansa Biopharma (Nasdaq Stockholm: HNSA) has reported that imlifidase (Idefirix) achieved 90% one-year graft failure-free survival in a post-authorization...
Foresee's leuprolide mesylate achieves 94% LH suppression in Phase III central precocious puberty trial
Foresee Pharmaceuticals (TPEx: 6576) reported that 94% of children with central precocious puberty achieved LH suppression to prepubertal levels in its...
Eli Lilly posts first data from Verve acquired in vivo base editor in hypercholesterolemia trial
Eli Lilly (NYSE: LLY) reported Phase Ib data from the Heart-2 trial showing that a single infusion of VERVE-102, an in vivo PCSK9 base editor, reduced LDL...
Novartis trying out mystery drug candidate for atopic dermatitis
An unidentified sponsor has registered a first-in-human trial of DCY636, an investigational drug whose molecular target has not been publicly disclosed, in...
Kelun, Merck's sac-TMT plus Keytruda cuts progression risk by 65% in advanced NSCLC
Kelun-Biotech (6990.HK) is presenting Phase III data at ASCO 2026 showing that sacituzumab tirumotecan combined with Merck's Keytruda (pembrolizumab) cut...
TreeFrog posts preclinical data for 3D neural microtissue therapy in Parkinson's disease
TreeFrog Therapeutics, a Bordeaux-based regenerative medicine biotech, reported preclinical data on TFG-001, its 3D neural microtissue cell therapy for...
Inovio's VGX-3100 meets primary endpoint in Phase III cervical dysplasia trial in China
ApolloBio, Inovio Pharmaceuticals' (Nasdaq: INO) Chinese partner, has announced that VGX-3100, a DNA immunotherapy targeting HPV16 and HPV18, met its...
Swedish Orphan Biovitrum's pozdeutinurad meets primary endpoint in Phase III gout trial
Swedish Orphan Biovitrum (STO: SOBI) reported that both doses of pozdeutinurad met the primary endpoint in the Phase III REDUCE 2 study, with 69.2% of...
Biogen and Denali's pull plug on LRRK2 inhibitor after Phase II failure in early Parkinson's
Biogen (Nasdaq: BIIB) and Denali Therapeutics (Nasdaq: DNLI) reported that BIIB122 (DNL151), a selective small-molecule LRRK2 inhibitor, failed to slow...
Boehringer Ingelheim's Hernexeos receives conditional approval in China for HER2-mutant advanced NSCLC
Boehringer Ingelheim has received conditional approval from China's National Medical Products Administration (NMPA) for zongertinib (Hernexeos) as a...
ASCO: 858 Therapeutics' posts 57% response rate for PARG inhibitor in BRCA-mutated ovarian and breast cancer
858 Therapeutics reported a 57% objective response rate for ETX-19477 in a small Phase 2-eligible subset of patients with BRCA-mutated platinum-resistant...
The AllSci Brief
Systematic R&D and deal news. Daily.